The China Medical University Hospital Clinical Trial Center (CMUH-CTC) is committed to enhancing clinical trials within our hospital by providing high-quality and efficient trial services. Since 2010, CMUH-CTC has received consistent support from the Ministry of Health and Welfare, ensuring that our trial quality meets international standards and facilitating the rapid market launch of new drugs and medical devices both domestically and internationally.
Over the years, CMUH-CTC has actively collaborated with the global pharmaceutical and medical industries, becoming a preferred partner for international pharmaceutical companies and contract research organizations. We have established strong partnerships with the top 50 global pharmaceutical companies. As of December 2024, CMUH-CTC has signed cooperation agreements with over 450 companies and successfully completed more than 1,800 clinical trial contracts.
With a well-established management system and exceptional trial execution capabilities, CMUH-CTC continues to advance clinical research development in Taiwan. We work alongside the global pharmaceutical industry to accelerate medical innovation and ultimately benefit patients.
China Medical University Hospital (CMUH) formally signed a Memorandum of Understanding (MOU) with AbbVie, a globally renowned biopharmaceutical company, on December 20, 2024, jointly committed to accelerating and innovating international clinical trials. This collaboration will combine China Medical University Hospital clinical research capabilities with AbbVie's global R&D resources to further enhance clinical trial efficiency and provide stronger support for new drug development in the Asia Pacific region.
Deepening Clinical Research Collaboration to Support International Medical Development
As a leading medical center in Taiwan, China Medical University Hospital has been actively involved in international clinical trials for a long time and has extensive research experience and expertise. By partnering with AbbVie, China Medical University Hospital will focus on trial process optimization, patient recruitment and data integration is expected to help thousands of patients participate in trials each year, drive international medical development and improve patient well-being.
Creating a New Benchmark for Clinical Trials Together
China Medical University Hospital indicated the cooperation not only symbolizes the deep trust between the two sides in the field of clinical research, but also establishes an important model of cooperation for the development of new drugs worldwide. Through this MOU, China Medical University Hospital will work with AbbVie to continue to drive clinical innovation and strengthen Taiwan's influence in the international biotechnology pharmaceutical landscape.
